Featured Publications

Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer.

Laine AM, Westover KD, Choy H Semin. Oncol. 2014 Feb 41 1 57-68

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

John C. Hunter, Deepak Gurbani, Scott B. Ficarro, Martin A. Carrasco, Sang Min Lim, Hwan Geun Choi, Ting Xie, Jarrod A. Marto, Zhe Chen, Nathanael S. Gray, and Kenneth D. Westover PNAS 2014 Early Edition

Stereotactic Ablative Radiotherapy (SABR) for Non-Small Cell Lung Cancer.

Iyengar P, Westover K, Timmerman RD Semin Respir Crit Care Med 2013 Dec 34 6 845-54

Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor.

Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Jänne PA, Meyerson M, Marto JA, Engen JR, Gray NS Angew. Chem. Int. Ed. Engl. 2013 Nov

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM and ATR.

Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS Cancer Res. 2013 Feb

Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.

Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI, Lindquist S Cell 2012 Aug 150 5 987-1001

Proton SBRT for medically inoperable stage I NSCLC.

Westover KD, Seco J, Adams JA, Lanuti M, Choi NC, Engelsman M, Willers H J Thorac Oncol 2012 Jun 7 6 1021-5

Treatment of non-small cell lung cancer patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with photon plans highlights importance of range uncertainty.

Seco J, Panahandeh HR, Westover K, Adams J, Willers H Int. J. Radiat. Oncol. Biol. Phys. 2012 May 83 1 354-61

Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.

Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV BJU international 2012 Apr

Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.

Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, Kang SA, Zhao J, Look AT, Sorger PK, Sabatini DM, Gray NS J. Biol. Chem. 2012 Mar 287 13 9742-52